However, because the median OS and PFS were almost similar to those of the Asia-Pacific trial for sorafenib 10 and the primary aim of this study was not the treatment efficacy of sorafenib, reflected by survival outcomes, but rather the study was performed to identify the predictors of treatment response, the influence of the potential selection bias might not be significant.
← all excerpts
Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
1
—
—